- HC Wainwright initiated reporting Aptorum Group Limited APM with a buy recommendation and a Price target of $8.
- The analyst is bullish on Aptorum based on three points:
- Promising preclinical efficacy of lead product candidate ALS-4, both as a standalone product and in combination with standard of care vancomycin, against Staphylococcus aureus (SA) infection.
- Blockbuster potential of in vivo neuroblastoma tumor reduction effect of SACT-1 in combination with SOC chemotherapy
- The significant potential of the Company’s nascent programs and ongoing collaborations to generate future value and, most importantly, near-term revenue.
- Related: Aptorum Highlights Updates on Clinical Validation of Molecular Diagnostics for RPIDD Infectious Diseases.
- Given Aptorum’s market cap of $39 million, the analyst believes the proceeds from Aptorum’s recent launch of NativusWell in Hong Kong alleviate concerns about near-term funding needs.
- HC Wainwright sees the shares as an attractive value proposition ahead of initiating a Phase 2a trial of ALS-4 in patients with SA infections, a Phase 1b/2a trial of SACT-1 in neuroblastoma, and expanding commercialization of NativusWell , viewed as positive catalysts by year-end 2022 or early 1Q23.
- Price promotion: APM shares are up 4.40% to $0.9292 on the latest check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
